INTRODUCTION
The population size today is increasing and becoming more of an aging population. This carries with it a package of chronic illnesses associated with aging and particularly the need for surgeries.
Atrial fibrillation is the most common arrhythmia causing approximately 20% of ischemic stroke cases with estimated annual costs of $6 billion in the United States 1, 2 . Many patients undergoing surgeries are on blood thinning agents; either oral antiplatelet (AP) for established coronary artery disease of anticoagulants (AC) for atrial fibrillation or thromboembolic disease, putting them at risk of bleeding. It is estimated that about 5-15% of patients undergoing coronary stent implantation are expected to undergo a surgical procedure within 2 years
Hence, it is of utmost importance to be familiar with the perioperative management of AP and AC agents to balance the risks of thromboembolic events, ischemic cardiac events and bleeding. The key to such management is extensive benefit-risk discussions with patients and seamless coordination within a multidisciplinary team of surgeons, interventional proceduralists, anesthesiologists, hematologists, vascular medicine specialists, cardiologists, primary care physicians and nurses. We present a case based multidisciplinary panel discussion to facilitate better understanding of this topic.
Before starting the case discussions, here are some definitions with respect to AC and AP agents:
• Interrupt: Omit one or more doses of the agent, based on the bleeding risk
• Bridge: Substitute the oral agent with a parenteral agent, based on the thrombotic risk
• Elective surgery: Can/should be delayed until the patient is medically stable.
• Urgent surgery: Needs to be done within 48 hours, needs quick attention and can be delayed for medical stability. This includes oncologic surgeries
• Emergent surgery: Needs to be done immediately, otherwise the patient will die.
The general approach to the perioperative management of blood thinners depends on 4 major steps . Estimating the thromboembolic risk depends on three main illness categories: presence of a mechanical heart valve, atrial fibrillation and venous thromboembolic disease. Patients at very high risk of thromboembolic phenomena should either be continued on their AC agents perioperatively or bridged with a parenteral agent. Patients with low to moderate risk of thromboembolic phenomena can be safely managed perioperatively off their AC agents in case of high risk of bleeding that necessitates cessation of the AC agent.
The thrombotic risk drives the decision for bridging and the bleeding risk drives the decision for AC interruption. A risk-benefit ratio will dictate the most suitable plan of action in every patient, and in most scenarios, these decisions differ from case to case. The bleeding risk is estimated based on surgical risk and patient's risk. A major bleed is generally defined as bleeding that is fatal, intracranial, requires surgery to correct, lowers the hemoglobin by ≥2 g/dL, or requires transfusion of ≥2 units of packed red blood cells
The goal of bridging is to minimize the patient's time being off the oral anticoagulant for more protection against thromboembolic events. The commonly used agents are subcutaneous enoxaparin or parenteral unfractionated heparin which have similar safety profiles and efficacy. However, the risk of bleeding should be also factored in while deciding when to start and stop the bridging agent. The available consensus statements on bridging management are summarized in table 3 4,7,8 .
To note, most of the above recommendations are either class 2b or 2c recommendations, and cannot be considered guidelines as per the definition of guidelines; rather they reflect consensus statements based on the published available body of evidence.
The following are transcription of case discussions among the different experts regarding their recommendations for perioperative management of each patient.
Case 1: Warfarin
A 76-year-old female with non-valvular atrial fibrillation, hypertension, and prior stroke six months ago, receiving warfarin, requires elective hip replacement with neuraxial anesthesia; renal function is normal, and weight is 75 kg.
CHA2DS2-VASc=6 → Very high risk of thrombosis and high risk of bleeding Dr. DeCaro: I tend to treat patients with a previous stroke aggressively irrespective of the time frame, so I would bridge this patient perioperatively.
Dr. Shwenck: We leave the decision to the orthopedic surgeons to determine the urgency of the procedure and if it can be delayed. We will still follow the currently available guidelines particularly concerning bridging.
Dr. DeCaro: We would also stop heparin at midnight prior to the procedure.
Dr.Merli:
There is a study in Annals of Internal Medicine 9 that showed no anti-Xa effect on the morning of the surgery if the enoxaparin is stopped 24 hours prior to surgery.
Audience: When we try to risk assess, we multiply the likelihood by the impact of an illness. For example, if 100 people had something done and 98% will do well, that's a great likelihood ration. The impact of having something go bad, such as paralysis can affect the remaining 2%. Therefore, when we individualize care, patients should understand the risks that they are agreeing to and quoting likelihood of success is less meaningful that weighing both the likelihood of success and impact of failure.
Dr. Merli: I don't think any orthopedic surgeon would allow their patients to receive a full dose of low molecular weight heparin (LMWH) on the same day after surgery, so they might recommend either lower doses or prophylactic doses.
Dr. Doherty: There was a survey that was recently sent out to the ACC members and asked :" Does your institution have a well structured process on how to manage perioperatively?"; and only one percent said they had a comprehensive well structured system on how to manage these patients perioperatively.
Audience: Can the panel comment on the appropriate time to stop heparin prior to surgery? We have had internal differences in opinions and recommendations.
Dr. Nagalla: The ACCP guidelines recommend stopping heparin 4-6 hours prior to surgery. For LMWH, the recommendation is at least 24 hours
4
. There are also some situations when we may need to use 40mg of enoxaparin instead of a therapeutic dose 24 hours prior to surgery in cases of high risk of bleeding in need for bridging therapy.
Suggested management plan for case 1:
• Stop warfarin day-5
• Preoperative bridging with LMWH day-3, with last dose on the morning of day-1.
• Resume warfarin within 24 hours after surgery (usual dose).
• Postoperative low dose LMWH for VTE prevention within 24 hours after surgery until postoperative bridging is started.
• Postoperative bridging on postoperative day 2 or 3, when hemostasis is secured; continue for at least 4-5 days, until the INR is therapeutic.
Case 2: Rivaroxaban
A 68-year-old female with non-valvular atrial fibrillation, hypertension, and congestive heart failure, receiving rivaroxaban 15 mg daily in the morning, requires a dental cleaning and two dental extractions; CrCl is 35 mL/min.
CHA2DS2-VASc score = 4 → high risk of thrombosis and low risk of bleeding Dr. Merli: I would not bridge this patient and would stop rivaroxaban. She is on the lower dose, so the question is when to stop it. ASRA guidelines 10 are not for dental procedures. Within 48 hours (4 half lives), rivaroxaban should be cleared, and 3 days for Xa inhibitors. I would restart rivaroxaban 24 hours after the procedure, and would think of an alternative drug for the future due to her low CrCl, such as warfarin.
Dr. Nagalla: I would treat her differently; I would not stop rivaroxaban and would use local pro-hemostatic agents such as tranexamic acid mouthwash. Hold dose on day of procedure, restart with next dose.
Dr. Ziring: In the community they are less tolerant of bleeding so we tend to stop the oral AC sooner.
Dr. Doherty: This would be a proceed-uninterrupted plan if a patient is taking Warfarin. The answer of this case might be different in 5 years due to the expanding data of direct acting anticoagulants (DOACS). Shall we delay the morning dose or omit the dose on that day?
Suggested management plan for case 2:
• Stop rivaroxaban on the day of the procedure.
• Use oral tranexamic acid mouthwash just before the procedure and two to three times that day after the procedure.
• Resume rivaroxaban the day after the procedure, after at least 24 hours have elapsed (assuming the dental extractions were uneventful).
Case 3: Apixaban
A 55 year old male with an unprovoked deep vein thrombosis (DVT) four months ago, receiving apixaban 5 mg twice daily, who requires a colonoscopy because of a personal history of premalignant colorectal polyps with planned polypectomy; renal function is normal.
→ high risk of thrombosis and high risk of bleeding
Dr. Nagalla: It was noticed that the highest risk of thrombosis recurrence is within 3 months of the VTE. In this case, since the DVT is >3 months ago, we would focus more on the bleeding risk as compared to the thrombotic risk; Stopping Apixaban 48 hours prior to the procedure is reasonable, with no bridging, and resuming Apixaban after 24hours. We can also give them 2.5mg of Apixaban 12 hours after the procedure then resume full dose 24hours after the procedure.
Dr. Merli: I agree with Dr. Nagalla, I would stop it 48 hours prior to the procedure. The guidelines from ASRA are for regional anesthesia, so we have to be careful in interpreting these results. Suggested management plan for case 3:
• Stop apixaban day-2
• No bridging
• Resume apixaban days 2-3 after the polypectomy/ colonoscopy.
Case 4: Warfarin
A 69-year-old male with chronic atrial fibrillation and hypertension on Warfarin, requires a Whipple surgery for pancreatic adenocarcinoma.
CHA2DS2-VASc score = 2 → low-moderate risk of thrombosis and high risk of bleeding Dr. Ziring: Moderate risk is based on CHA2DS2-VASc risk but this patient has other risks of thrombosis: cancer and undergoing a major surgery. Therefore here are two approaches:
• Not bridge and restart coumadin + Sub-cutaneous heparin DVT prophylaxis
• LMWH before surgery, discontinue it prior to surgery, after surgery restart LMWH at lower dose, increase to full dose at time of discharge. Removes this confusion of pills and bridging.
Dr.Doherty: If the patient is ambulatory, the thrombotic risk is acceptably low. Risk is not stroke or systemic embolism; rather it is mainly of DVT. Therefore, post-op needs prophylactic dose prior to full dose enoxaparin or warfarin.
Dr. DeCaro: So post-op, transitioning to Warfarin, I would give DVT prophylaxis until INR is therapeutic on Warfarin.
Dr. Nagalla: There is an advantage of Warfarin post-op. Bowel resection; the advantage of using warfarin is that we have an INR to monitor as compared to DOACs. Patients on DOACs were excluded from most studies.
Suggested management plan for case 4:
• Stop Warfarin day-5
• Resume Warfarin day of surgery.
• Use sub-cutaneous heparin or LMWH for DVT prophylaxis on day of surgery onwards until INR is therapeutic
Case 5: Rivaroxaban and regional anesthesia
A 65 yo male with history of AF and hypertension taking rivaroxaban presents for primary total hip replacement. He denies any history of diabetes, coronary artery disease, stroke, or heart failure. Hemoglobin 14.0.
CHA2DS2-VASc score = 2 → low-moderate risk of thrombosis and low risk of bleeding Suggested management plan for case 5:
• Stop Rivaroxaban day-3 to reduce risk of spinal hematoma (may need longer with impaired CrCl or other agents that increase bleeding risk)
• No Bridging
• Resume Rivaroxaban day +1, if team prefers to delay, consider LMWH or SQH for DVT prophylaxis
Perioperative management of AP agents
The general approach to managing patients on antiplatelet agents preoperatively is similar to that for Anticoagulant agents. Defining the fine balance between ischemic and bleeding risk remains a challenge in patients with coronary stents undergoing surgery treated with antiplatelet therapy. The risk of recurrent ischemic events for patients discontinuing or not adhering to aspirin treatment has been suggested to increase 3-fold
12
. Stent thrombosis is a serious complication that commonly presents with death or a significant nonfatal myocardial infarction. Ischemic events are more common after the premature discontinuation of a second antiplatelet agent such as clopidogrel and it can be explained by "withdrawal of protection"
12 . This can be accomplished by avoiding drug-eluting stents whenever possible, especially in patients with known poor adherence to medical therapy and with any anticipated surgeries. Low risk situations are defined as > 14 days post balloon angioplasty, > 6 weeks post bare metal stent and > 6 months post drug eluting stent. If the patients is at low risk of major adverse cardiac events and have a low risk of bleeding, then the dual AP agents can be discontinued, but it is preferred if Aspirin is continued. In patients who had an MI, the observational data shows that up to a year there are complications with non-cardiac surgeries. We don't use sirolimus stents anymore, which are considered first generation stents. But if we had a patient with that such as in our case, and is beyond a year, we would be comfortable stopping the second AP agents but not the aspirin (ASA). Therefore, with a first generation stent, we would continue the surgery on ASA. We would push for surgery on double AP agents if it is 4 months post stenting, or delay the surgery to at least 1 year and then do the surgery only on ASA. If the case is of a second-generation stent, there is data with xerolimus and everolimus that showed evidence of 3 months of dual AP therapy is enough, but keep in mind that an NSTEMI was recent.
Dr. DeCaro: Our surgeons have reached a certain comfort level performing surgeries on dual AP agents.
Dr. Nagalla: One option might be to stop the AP agent, bridge with heparin and then restart the agent post-op.
Audience: This area needs more evidence to know how to manage AP agents. We have to respect the surgeon's preferences, even if it is anecdotal or cultural rather than evidence based since they are the ones performing the surgery.
Suggested management plan for case 6:
• Optimal to delay surgery to at least 6 months after DES
• Since it is urgent due to active malignancy, and low risk of bleed, will proceed with surgery on DAPT without interruption.
CONCLUSION
Managing patients on blood thinners perioperatively can be very challenging and an optimal approach is an interdisciplinary discussion weighing the benefits to risks of stopping the agent or bridging whenever necessary. Patients should be fully informed of the risks of thrombosis versus bleeding when consenting to the plan. The available consensus statements have been serving as "guidelines", but as our expert panelists have reminded us, they are class 2 recommendations formed by expert consensus. It is important to take these recommendations in the context of every patient for an individualized approach to treatment.
